66607-95-2 Usage
Explanation
Different sources of media describe the Explanation of 66607-95-2 differently. You can refer to the following data:
1. The molecular formula represents the number of atoms of each element present in a molecule of the compound.
2. It is a derivative of benzisoxazolone, which means it is structurally related to benzisoxazolone with some modifications.
3. The methoxy group (-OCH3) is attached to the fifth carbon atom in the benzisoxazolone ring, which differentiates it from other benzisoxazolone derivatives.
4. The compound has potential pharmaceutical applications, meaning it may be used in the development of drugs or medications.
5. It may have potential biological applications, which could include interactions with biological systems or organisms.
6. The compound can be used in the synthesis of various organic compounds, which are essential in the development of new materials and chemicals.
7. It may be used in the synthesis of pharmaceutical drugs, contributing to the development of new medications.
8. The specific properties and potential uses of 1,2-Benzisoxazol-3(2H)-one,5-methoxy-(9CI) are still being studied and explored by researchers in the fields of chemistry, pharmacology, and medicine.
Derivative of Benzisoxazolone
Yes
Methoxy Group Attachment
Fifth carbon atom of the benzisoxazolone ring
Potential Pharmaceutical Applications
Yes
Potential Biological Applications
Yes
Synthesis of Organic Compounds
Yes
Synthesis of Pharmaceutical Drugs
Yes
Ongoing Research
Chemistry, Pharmacology, and Medicine
Check Digit Verification of cas no
The CAS Registry Mumber 66607-95-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,6,6,0 and 7 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 66607-95:
(7*6)+(6*6)+(5*6)+(4*0)+(3*7)+(2*9)+(1*5)=152
152 % 10 = 2
So 66607-95-2 is a valid CAS Registry Number.
66607-95-2Relevant articles and documents
Benzo[d]isoxazol-3-ol DAAO inhibitors
-
Page/Page column 9, (2010/02/12)
Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia, or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutic amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein Z1 is N or CR3; Z2 is N or CR4; Z3is O or S; A is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc or a mixture thereof; R1, R2, R3 and R4 are independently selected from hydrogen, alkyl, hydroxy alkoxy, aryl, acyl, halo, cyano, haloalkyl, NHCOOR5 and SO2NH2; R5 is aryl, arylalkyl, heteroaryl or heteroarylalkyl; at least one of R1, R2, R3 and R4 is other than hydrogen; and at least one of Z1 and Z2 is other than N.
